Additional biomarker analyses were conducted to determine whether there is a relationship between changes in ctDNA levels, as measured by ROS1 fusion levels and cTF, and tumor response over the duration of treatment (Extended Data Fig. 7). The gene discussed is ROS1; the disease is neoplasm.